Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials

INTRODUCTION: Low disease activity (LDA)/remission is the target of treatment in patients with psoriatic arthritis (PsA). We assessed the proportions of patients with PsA receiving upadacitinib who achieved LDA/remission over 1 year. METHODS: This was a post hoc analysis of the double-blind, placebo...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip, Kavanaugh, Arthur, Gladman, Dafna, FitzGerald, Oliver, Soriano, Enrique R., Nash, Peter, Feng, Dai, Lertratanakul, Apinya, Douglas, Kevin, Lippe, Ralph, Gossec, Laure
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314475/
https://www.ncbi.nlm.nih.gov/pubmed/35606663
http://dx.doi.org/10.1007/s40744-022-00449-6

Ejemplares similares

Ejemplares similares